Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 151 participants.

Also called NCT02393612

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 151 participants (enrolled count) (from the registry)
Sponsor
Alvogen Korea (from the registry)
Registry
  • NCT NCT02393612
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02393612. Randomized; triple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-04 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Clinical Trial to Evaluate Efficacy and Safety of DP-R202 and Anplag in Patients With Artery Occlusive Disease
Acronym
DAVICI
Condition
Peripheral Arterial Disease
Intervention (Drug)
DP-R202
Intervention (Drug)
Anplag tab
Lead sponsor
Alvogen Korea (class: industry)

Record details

Record id
cardio:ct-nct02393612
Content hash
80724831bc0980b22d54db7396775cf921afd844b987a2f2fefa807435ee9cc7